“100% effectiveness against severe cases”


AstraZeneca’s anti-Covid vaccine is 80% effective even for those over 65. This is what emerges from a phase 3 study conducted in the US which demonstrated “a statistically significant 79% efficacy in preventing symptomatic infection and 100% in preventing serious illness and hospitalizations “. This was announced by the Anglo-Swedish pharmaceutical group, underlining that “the effectiveness of the vaccine was consistent” in the various groups of “ethnicity and age” examined. In particular, “in participants aged 65 and over, the efficacy was 80%”.

“AstraZeneca will continue to analyze the efficacy and safety data” emerging from the Covid vaccine studies developed with the University of Oxford, and is preparing “a primary analysis to be submitted to the US Food and Drug Administration”, the Agency American for the Fda drug, “for the authorization for emergency use in the coming weeks”, explains the Anglo-Swedish company. “In parallel – reads a note – the primary analysis will be presented for publication in a peer-reviewed journal”.

The new results “add to the growing evidence that this vaccine is well tolerated and highly effective against Covid-19 at all severity levels and in all age groups – said Mene Pangalos, Executive Vice President BioPharmaceuticals R&D at AstraZeneca – We are confident that this vaccine can play an important role in protecting millions of people around the world from a lethal virus. We are preparing to present these findings to the Food and Drug Administration – he confirms – and to launch millions of doses across America in case the vaccine gets authorization for emergency use in the United States. “

“AstraZeneca continues to engage with governments, multilateral organizations and collaborators around the world to ensure broad and equitable access to the nonprofit vaccine throughout the duration of the pandemic,” notes the company.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick